Patents by Inventor Rosanne Catalano

Rosanne Catalano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prevention and treatment of amyloid-associated disorders
    Publication number: 20060210964
    Abstract: The present invention provides assays to identify compounds that affect microglial cell activation, and specifically assays to identify compounds that affect secretion of cytokines from these microglial cells by modulating PGE2-mediated activity. The assays of the invention include assays for testing microglial cell activation by contacting microglia with compounds that modulate ?-amyloid PGE2-mediated activation, which can be identified by cellular activity such as secretion of cytokines, e.g., TNF-? and IL-1?,. The effect of the candidate compound can be determined by comparing the effect with a control culture which is not contacted with the compound, or by comparing the effect with a standardized profile.
    Type: Application
    Filed: May 10, 2006
    Publication date: September 21, 2006
    Inventors: Paul Hyslop, Foy Miller, Linda Higgins, Rosanne Catalano, Barbara Cordell, Elzbieta Puchacz
  • Prevention and treatment of amyloid-associated disorders
    Publication number: 20040067538
    Abstract: The present invention provides assays to identify compounds that affect microglial cell activation, and specifically assays to identify compounds that affect secretion of cytokines from these microglial cells by modulating PGE2-mediated activity. The assays of the invention include assays for testing microglial cell activation by contacting microglia with compounds that modulate &bgr;-amyloid PGE2-mediated activation, which can be identified by cellular activity such as secretion of cytokines, e.g., TNF-&agr; and IL-1&agr;. The effect of the candidate compound can be determined by comparing the effect with a control culture which is not contacted with the compound, or by comparing the effect with a standardized profile.
    Type: Application
    Filed: July 21, 2003
    Publication date: April 8, 2004
    Inventors: Paul Andrew Hyslop, Foy Dean Miller, Linda S. Higgins, Rosanne Catalano, Barbara Cordell, Elzbieta Puchacz
  • Prevention and treatment of amyloid-associated disorders
    Patent number: 6596474
    Abstract: The present invention provides assays to identify compounds that affect microglial cell activation, and specifically assays to identify compounds that affect secretion of cytokines from these microglial cells by modulating PGE2-mediated activity. The assays of the invention include assays for testing microglial cell activation by contacting microglia with compounds that modulate &bgr;-amyloid PGE2-mediated activation, which can be identified by cellular activity such as secretion of cytokines, e.g., TNF-&agr; and IL-1&agr;. The effect of the candidate compound can be determined by comparing the effect with a control culture which is not contacted with the compound, or by comparing the effect with a standardized profile.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: July 22, 2003
    Assignees: Scios Inc., Eli Lilly and Company
    Inventors: Paul Andrew Hyslop, Foy Dean Miller, Linda S. Higgins, Rosanne Catalano, Barbara Cordell, Elizbieta Puchacz